Dr. Robert Schwartz, Chief Medical Officer of Autonomix, discusses key learnings from initial trial phase (“POC 1”) where clinically meaningful pain reduction was demonstrated Outlines Company’s plans to initiate market expansion study (“POC 2”) into additional visceral cancers and earlier stage pancreatic cancer, expected to begin Q2 2025 Access the “What This Means” video here THE WOODLANDS, TX, May 01, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medic ...

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Q4 2024 Earnings Conference Call February 25, 2025 8:30 AM ET Company Participants Jeffrey Dayno - President, Chief Executive Officer Jeffrey Dierks - Chief Commercial Officer Kumar Budur - Chief Medical Officer, Scientific Officer Sandip Kapadia - Chief Financial Officer, Chief Administrative Officer Brennan Doyle - Head of Investor Relations Conference Call Participants Charles Duncan - Cantor Fitzgerald John Gregory Dean - Oppenheimer David Amsellem - Pipe ...